Keros Therapeutics

Keros Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with unmet medical need. The company was founded in 2015 and is headquartered in Lexington, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Keros Therapeutics Inc (NASDAQ: KROS), a clinical-stage biopharma focused on the development of treatments for rare hematologic and musculoskeletal disorders, went public in April.

3 Keros Analysts On Why Biopharma Is A Compelling Investment Opportunity

Zentalis Pharmaceuticals

These companies just raised significant cash to advance promising drug pipelines.

These 3 Biotechs Had Successful IPOs During the Coronavirus Crisis. Are They Buys?

The Covid-19 pandemic has waylaid what was supposed to be an active year in biotech initial public offerings.

Keros Therapeutics Shares Climb 70% After First Post-Covid-19 Biotech IPO

LEXINGTON, Mass., April  13, 2020  (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need, today announced the closing of its initial public offering of 6,900,000 shares of common stock, which includes the exercise in full by the underwriters of their option to purchase up to 900,000 additional shares, at a public offering price of $16.00 per share, for total gross proceeds of $110.4 million, before deducting underwriting discounts and commissions and estimated offering expenses. All of the shares of common stock were sold by Keros.

Keros Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Keros Therapeutics finished the week up 35%, affirming that the biotech industry won't be deterred by current market volatility.

U.S. IPO Weekly Recap: Keros Therapeutics Rises 35% As Biotechs Beat The IPO Shutdown

News for Keros Therapeutics Stock (KROS)